Saturday 17 October 2026
Export MBOT’s income statement to Excel — free account
Microbot Medical Inc.
MBOT Healthcare Medical Instruments & Supplies
In the quarter to June 2026, revenue grew 1,047.6%, EPS grew 20.0% and free cash flow fell 98.7%, each against the same quarter a year earlier.
0.95
0.00
0.00%
Follow MBOT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
317.04 | 838.17 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(26.25) | (32.03) | — | — | |
P/B ratio |
1.90 | 2.18 | — | — | |
Price to Tangible BV |
1.90 | 2.19 | — | — | |
EV/Sales |
159.71 | 475.01 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(3.74) | (6.02) | — | — | |
EV/FCF |
(3.68) | (5.96) | — | — | |
Quick Ratio |
17.42 | 21.50 | 22.97 | 27.34 | |
Current Ratio |
18.56 | 22.59 | 23.33 | 27.53 | |
Net Debt/EBITDA |
10.95 | 16.74 | 18.90 | 20.83 | |
Debt/Assets |
0.00% | 0.74% | 0.70% | 0.00% | |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.00 | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.89 | 1.38 | 1.08 | 1.07 | |
Capex/Depreciation |
(9.47) | (9.00) | (2.50) | (1.30) | |
Research and Development Expense of Revenue |
772.20% | 1,231.43% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,528.63% | 2,884.76% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
179.67% | 211.43% | 0.00% | 0.00% | |
Graham Net Nets |
0.52 | 0.45 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(12.31%) | (10.79%) | — | — | |
Free Cash Flow Yield |
(13.69%) | (9.50%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.07) | (0.08) | (0.08) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.08) | (0.08) | (0.08) | |
Cash per Share |
1.01 | 1.08 | 1.72 | 1.67 | |
Shareholders Equity per Share |
1.03 | 1.10 | 1.69 | 1.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.03 | 1.10 | 1.69 | 1.63 | |
Free Cash Flow |
(5.13) | (5.16) | (3.78) | (3.85) | |
Working Capital |
68.29 | 73.14 | 76.40 | 77.85 | |
Capital Expenditures |
(0.14) | (0.11) | (0.02) | (0.01) | |
Net Current Asset Value |
67.74 | 72.57 | 75.83 | 77.25 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.59 | 1.03 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.18 | 0.22 | — | — | |
Average Payables |
0.69 | 0.64 | 0.34 | 0.38 | |
Average Assets |
53.25 | 54.48 | 43.79 | 43.48 | |
Average Common Equity |
49.64 | 51.53 | 40.54 | 41.02 |
Columns are period end dates